M&G Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

M&G Investment Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-257	Closed	-$211K	–	426
2023 Q1	$211K	Sell	257 -6,979	-96%	-$5.26M	﹤0.01%	383
2022 Q4	$5.22M	Hold	7,236	–	–	0.03%	218
2022 Q3	$4.99M	Sell	7,236 -15	-0.2%	-$9.44K	0.03%	220
2022 Q2	$4.29M	Sell	7,251 -107	-1%	-$69.6K	0.03%	259
2022 Q1	$5.14M	Sell	7,358 -13	-0.2%	-$8.22K	0.01%	253
2021 Q4	$4.66M	Sell	7,371 -13,337	-64%	-$8.2M	0.01%	258
2021 Q3	$12.5M	Buy	20,708 +8,741	+73%	+$5.43M	0.03%	248
2021 Q2	$6.69M	Sell	11,967 -915	-7%	-$464K	0.02%	347
2021 Q1	$6.09M	Sell	12,882 -1,440	-10%	-$701K	0.02%	222
2020 Q4	$6.92M	Buy	14,322 +410	+3%	+$221K	0.04%	212
2020 Q3	$7.79M	Sell	13,912 -1,427	-9%	-$865K	0.08%	187
2020 Q2	$9.57M	Buy	15,339 +6,613	+76%	+$3.75M	0.1%	167
2020 Q1	$4.26M	Sell	8,726 -1,629	-16%	-$672K	0.05%	217
2019 Q4	$3.88M	Buy	+10,355	New	+$3.48M	0.03%	245

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

M&G Investment Management's REGN Position: Q2 2023 in Review

M&G Investment Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2023, closing a stake of 257 shares — an estimated $211K sold.

M&G Investment Management first reported a position in REGN in Q4 2019 and held it in 14 quarters. The position peaked at $12.5M in Q3 2021. 1,164 funds tracked by Wall St. Rank hold REGN as of Q2 2023.

M&G Investment Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
M&G Investment Management sold 257 Regeneron Pharmaceuticals shares in Q2 2023, an estimated $211K.
M&G Investment Management first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 14 quarters.
M&G Investment Management's Regeneron Pharmaceuticals position peaked at $12.5M in Q3 2021.
1,164 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2023.

Based on M&G Investment Management's 13F filing for Q2 2023, filed 1 Aug 2023.